Abstracts tagged "oral"

Abstract Number: 1720 • 2019 ACR/ARP Annual Meeting
Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome
Gulen Hatemi¹, Berna Yurttas ², Zekayi Kutlubay ³, Tim Cote ⁴, Semsi Burak Derkunt ⁴, Yusuf Yazici ⁵ and Hasan Yazici ⁶, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University- Cerrahpasa, Behçet's Disease Research Center, Istanbul, Turkey, Istanbul, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ⁴Silk Road Therapeutics, Washington, DC, USA, Washington, WA, ⁵New York University School of Medicine, New York, NY, USA, New York, NY, ⁶Academic Hospital, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Oral ulcers, the hallmark lesion of Behçet’s syndrome (BS) can be disabling and impair eating, drinking and speaking. Despite recent advances in systemic medications…
Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
René-Marc Flipo¹, Alain Saraux², Christophe Hudry³, Cécile Gaujoux-Viala⁴, Eric Senbel⁵, Sonia Tropé⁶, Elena Zinovieva⁷, Agnès Courbeyrette⁸ and Hélène Herman-Demars⁷, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology, CHU Brest, Brest, France, ³AP-HP Hôpital Cochin, Paris, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology office, Marseille, France, ⁶149 avenue du Maine, ANDAR, Paris, France, ⁷Medical Department Nordic Pharma, Paris, France, ⁸Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
Abstract Number: 2017 • 2018 ACR/ARHP Annual Meeting
Oral Microbiota in New-Onset Juvenile Idiopathic Arthritis
Albert Chow^1,2,3, Sriharsha Grevich^1,2,3, Peggy Lee⁴, Jeffrey McLean⁴, Sarah Ringold^1,3,5, Roger Bumgarner⁶ and Anne Stevens^1,2,3, ¹Pediatrics, University of Washington, Seattle, WA, ²Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ³Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ⁴Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, ⁶Microbiology, University of Washington, Seattle, WA
Background/Purpose: Oral microbial dysbiosis of specific organisms such as Porphyromonas, Aggregatibacter, Tannerella, and Treponema in dental plaque has been implicated in the pathogenesis of adult…
Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting
Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Fouad Fayad¹, Nelly Ziade², Georges Merheb^3,4, Said Attoui⁵, Alla Aiko⁶, Kamel Mroue⁵ and Abdel Fattah Masri⁷, ¹Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Holly Spirit University, Kaslik, Lebanon, ⁵Hammoud University Medical Center, Saida, Lebanon, ⁶Saint Georges Hospital, Beirut, Lebanon, ⁷American University of Beirut Medical Center, Beirut, Lebanon
Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
Abstract Number: 723 • 2015 ACR/ARHP Annual Meeting
Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation
Robert Durcan¹, Wei Fu² and Michelle Petri³, ¹Beaumont Hospital, Dublin, Ireland, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Oral ulcers (OU) are a common manifestation of systemic lupus erythematosus (SLE). They are included in both classification criteria and disease activity indices. Despite…
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 1694 • 2014 ACR/ARHP Annual Meeting
a Feasibility Study of Subjective and Objective Assessment of Sublingual Abnormalities in Systemic Sclerosis
Tracy M. Frech¹, John Pauling², Maureen Murtaugh³, Lee S. Shapiro⁴, Bernard Choi⁵, Ryan Farraro⁵ and Robyn T. Domsic⁶, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom, ³Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ⁴The Center for Rheumatology, Albany, NY, ⁵University of Irvine, Irvine, CA, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Sublingual frenulum abnormalities are reported in systemic sclerosis (SSc), but the exact nature and clinical relevance of such abnormalities is unknown. Laser speckle contrast…
Abstract Number: 342 • 2012 ACR/ARHP Annual Meeting
Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Shireen Vali¹, Canio Refino², Jay Dela Cruz², Robinson Vidva¹, Prashant Nair¹, Saumya Radhakrishnan¹, Pradeep Fernandes¹, Taher Abbasi¹ and Gurkirpal Singh³, ¹CellWorks Group, Saratoga, CA, ²InTouch Bio, Alameda, CA, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves a complex interaction of multiple cell systems, cytokines and mediators. We recently developed a predictive software-based mathematical model that emulates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].